Atypical anti-psychotics in the real world - A naturalistic comparative outcome study

Scottish Medical Journal

Volumn 50, Issue 3, 2005, Pages 102-106

  Taylor, Mark ^a   Turner, M ^b   Watt, L ^b   Brown, D ^b   Martin, M ^b   Fraser, K ^b  

^a Springpark Centre   (United Kingdom)

^b NONE

Author keywords

Anti psychotics; Atypical

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE STUDY; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OUTCOMES RESEARCH; PARAMETER; POSITIVE SYNDROME; PRESCRIPTION; PROSPECTIVE STUDY; PSYCHOSIS; QUALITY OF LIFE; RATING SCALE; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 24644512210     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1177/003693300505000305     Document Type: Article

References (14)

1. Kane JM, Leucht S, Carpenter D, Docherty JP (eds.) The Expert Consensus Guideline Series: Optimising the pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003; 64 (suppl 12) 1-98.
2. Conley RR and Mahmoud R. A randomised double blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158: 765-774.
3. Tran PV, Hamilton SH, Kuntz AJ, et al. Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacology 1997; 17:407-18.
4. Gilchrist A, Taylor M, Wright M, Drury K, Short A, Steel R, Murray P and Lawrie S. Is olanzapine clinically effective? A naturalistic outcome survey in two hospital settings. Pharmaceutical Journal 2002. 269, 222-5.
5. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomised controlled trials. Am J Psychiatry 2002; 159: 180-90.
6. Kasper S, Rosillon D and Duchesne I on behalf of the RODOS Investigator group. Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacology 2001; 16: 179-87.
7. Jones PB, Lepine JP, and Pancheri P, eds. European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand. 2003; 107 (Suppl 416).
8. Ho BC, Miller D, Nopoulos P, et al. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999; 60:658-63.
9. Leucht S, Pitschel-Walz G, Abraham D, and Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials. Schiz Research 1999; 35 51-68.
10. Tuunainen A, Wahlbeck K, and Gilbody S. Newer atypical antipsychotic medication incomparison to clozapine: a systematic review of randomised trials. Schiz Research 2002; 56, 1-10.
11. Karow A and Naber D. Subjective well being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002; 162 (1): 3-10.
12. Sackett DL, Haynes RB, Guyatt GH, et al. Clinical Epidemiology. A basic science forclinical medicine. eds Boston: Little, 1991. Brown & Co.
13. Mojtabai R, Nicholson RA. (1995). Interrater reliability of ratings of delusions and bizarre delusions. Am J Psychiatry 1995; 152:1804-6.
14. Tandon R, and Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 28 9-26.